Suppr超能文献

巴雷特食管T1a期腺癌的多学科治疗:生理状况良好患者内镜治疗与手术治疗的当代比较

Multidisciplinary treatment of T1a adenocarcinoma in Barrett's esophagus: contemporary comparison of endoscopic and surgical treatment in physiologically fit patients.

作者信息

Schmidt Henner M, Mohiuddin Kamran, Bodnar Artur M, El Lakis Mustapha, Kaplan Stephen, Irani Shayan, Gan Ian, Ross Andrew, Low Donald E

机构信息

Section of General Thoracic Surgery, Department for General, Thoracic and Vascular Surgery, Virginia Mason Medical Center, 1100 Ninth Ave. C6-SUR, Seattle, WA, 98111, USA.

Department of Hepatology and Gastroenterology, Virginia Mason Medical Center, Seattle, WA, USA.

出版信息

Surg Endosc. 2016 Aug;30(8):3391-401. doi: 10.1007/s00464-015-4621-z. Epub 2015 Nov 5.

Abstract

BACKGROUND

Previous reports comparing endoscopic therapy (ET) and surgical therapy (ST) have predominantly assessed patients with high-grade dysplasia. The study aim was to compare ET to ST in physiologically fit patients with cT1a adenocarcinoma (EAC).

METHODS

Review of two prospective databases yielded 100 patients presenting with clinical cT1a EAC between 2000 and 2013. Only physiologically fit patients who were candidates for either treatment were analyzed.

RESULTS

Presenting patient characteristics were similar between ET (n = 36) and ST groups (n = 49). Surgical patients were less likely to be staged with EMR (43 vs 100 %) and were associated with mass lesions >1 cm at EGD (p = 0.01), multifocal EAC (p = 0.03), and positive margins for EAC on EMR (p < 0.05). On multivariate analysis, only multifocal HGD was an independent factor for surgery. Following esophagectomy, R0 resection rates for Barrett's esophagus and cancer were 100 %. Incidence of surgery decreased over the study period from 85 to 25 %. All ET patients had EMR, and 28 patients underwent additional ablative therapies for Barrett's esophagus. Following ET, eradication rates of EAC, dysplasia, and BE were 92, 81, and 53 %, respectively. Morbidity rates were comparable between groups (ST 51 % vs ET 39 %, p = 0.31). In-hospital mortality rate was zero in each group. Recurrence rates in ST and ET group were 2 and 11 % (p = 0.08). In the ET group, two patients with endoluminal cancer recurrence after complete eradication underwent esophagectomy. Age-adjusted overall survival was comparable.

CONCLUSION

In high-volume esophageal centers, ST and ET provide equally safe and effective treatment for cT1a EAC in medically fit patients. While the results of this study provide a historical perspective and clearly demonstrate an evolution toward ET over time, the appropriate treatment modality is best selected in a multidisciplinary fashion with EMR providing the most accurate staging. In endoscopically treated patients, indefinite endoscopic follow-up required, however, standardized long-term follow-up protocols are needed.

摘要

背景

既往比较内镜治疗(ET)和手术治疗(ST)的报告主要评估了高级别异型增生患者。本研究旨在比较ET与ST在生理状况适合的cT1a期腺癌(EAC)患者中的疗效。

方法

回顾两个前瞻性数据库,纳入2000年至2013年间表现为临床cT1a期EAC的100例患者。仅分析生理状况适合且适合两种治疗方法之一的患者。

结果

ET组(n = 36)和ST组(n = 49)患者的基线特征相似。手术患者接受内镜下黏膜切除术(EMR)分期的可能性较小(43%对100%),且与内镜检查时肿块病变>1 cm(p = 0.01)、多灶性EAC(p = 0.03)以及EMR时EAC切缘阳性(p < 0.05)相关。多因素分析显示,仅多灶性高级别异型增生是手术的独立因素。食管切除术后,Barrett食管和癌症的R0切除率为100%。研究期间手术发生率从85%降至25%。所有ET患者均接受了EMR,28例患者因Barrett食管接受了额外的消融治疗。ET治疗后,EAC、异型增生和Barrett食管的根除率分别为92%、81%和53%。两组的发病率相当(ST组51%对ET组39%,p = 0.31)。每组的院内死亡率均为零。ST组和ET组的复发率分别为2%和11%(p = 0.08)。在ET组中,两名完全根除后腔内癌复发的患者接受了食管切除术。年龄调整后的总生存率相当。

结论

在大型食管中心,ST和ET为生理状况适合的cT1a期EAC患者提供了同样安全有效的治疗。虽然本研究结果提供了一个历史视角,并清楚地表明随着时间推移向ET的演变,但最合适的治疗方式最好通过多学科方式选择,EMR可提供最准确的分期。在内镜治疗的患者中,需要进行无限期的内镜随访,然而,需要标准化的长期随访方案。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验